Wedbush Comments on Synlogic’s FY2022 Earnings (NASDAQ:SYBX)

Synlogic (NASDAQ:SYBX) – Stock analysts at Wedbush issued their FY2022 earnings per share estimates for Synlogic in a research note issued to investors on Tuesday, March 13th, according to Zacks Investment Research. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings per share of ($1.17) for the year.

How to Become a New Pot Stock Millionaire

A number of other equities analysts also recently issued reports on SYBX. HC Wainwright set a $20.00 target price on Synlogic and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research raised Synlogic from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Piper Jaffray started coverage on Synlogic in a research note on Monday, January 29th. They set an “overweight” rating and a $16.00 target price for the company. Finally, ValuEngine downgraded Synlogic from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $19.00.

SYBX traded up $0.52 on Thursday, hitting $9.70. 196,520 shares of the company traded hands, compared to its average volume of 91,541. The company has a quick ratio of 9.82, a current ratio of 9.82 and a debt-to-equity ratio of 0.01. The company has a market cap of $215.07, a PE ratio of -1.65 and a beta of 2.22. Synlogic has a 12-month low of $8.76 and a 12-month high of $23.00.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Tuesday, March 20th. The biotechnology company reported ($0.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.07. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.11 million.

Several hedge funds have recently modified their holdings of SYBX. Artal Group S.A. acquired a new stake in shares of Synlogic in the 4th quarter worth approximately $5,335,000. Renaissance Technologies LLC acquired a new stake in shares of Synlogic in the 4th quarter worth approximately $191,000. Deutsche Bank AG grew its holdings in shares of Synlogic by 204.0% in the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 13,200 shares during the period. Finally, Spark Investment Management LLC acquired a new stake in shares of Synlogic in the 4th quarter worth approximately $105,000. 48.97% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Wedbush Comments on Synlogic’s FY2022 Earnings (NASDAQ:SYBX)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/wedbush-comments-on-synlogic-incs-fy2022-earnings-sybx.html.

Synlogic Company Profile

Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply